DURECT Corporation to Present at the H.C. Wainwright Global Investment Conference

Core Insights - DURECT Corporation is a late-stage biopharmaceutical company focused on developing epigenetic therapies for serious conditions like acute organ injury and cancer [3] - The company will participate in the H.C. Wainwright 26th Annual Global Investment Conference from September 9-11, 2024, in New York City [1][2] Company Overview - DURECT's lead drug candidate, larsucosterol, targets dysregulated DNA methylation and is in clinical development for alcohol-associated hepatitis (AH) and metabolic dysfunction-associated steatohepatitis (MASH) [3] - Larsucosterol has received Fast Track and Breakthrough Therapy designations from the FDA for the treatment of AH [3] - POSIMIR®, a non-opioid analgesic developed using the SABER® platform technology, is FDA-approved and licensed to Innocoll Pharmaceuticals for distribution in the U.S. [3] Future Outlook - The company is exploring the potential of larsucosterol for various indications, with ongoing clinical trials [4]